Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Uveitis

In brief

Primary Objective: To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU). Secondary Objectives: To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant therapy. To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with anti-drug antibodies (ADA).

Key facts

Study ID

NCT01900431

Run by

Sanofi

People needed

58

Starts

2013-10-01

Expected to finish

2016-04-01

Last updated by the study team

2017-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age.
• Non-infectious intermediate, posterior, or pan-uveitis in the study eye.
• Active disease at screening or evidence of activity within the 3 months prior to screening visit. Following the approval of amendment-2, only participants with "active disease" as defined above were enrolled in the study.
• Starting oral prednisone dose must be greater than or equal to 15 mg/day and less than 80 mg/day.
• At screening, participants must be receiving oral prednisone (≥15 mg and <80 mg/day [or equivalent oral corticosteroid]) as single immunosuppressive therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous). -
• Participants could be receiving one or several of the following therapies: Azathioprine (≤2.5 mg/kg/day), Mycophenolate mofetil (≤2 g daily, orally), Cyclosporine (≤4 mg/kg daily, orally), Tacrolimus (≤4 mg daily, orally).
• The doses might not had been increased for at least 4 weeks prior to the randomization visit.
• At randomization, participants had been receiving oral prednisone (≥15 mg and <80 mg/day [or equivalent oral corticosteroid]) as single immunosuppressive therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous).
• Azathioprine, mycophenolate mofetil, cyclosporine and tacrolimus had to be permanently discontinued at least 48 hours prior to the first study treatment injection, or longer as per Investigator's judgment. These immunomodulatory therapies (IMTs) were not permitted anytime during the treatment period.
• Signed written informed consent.

You may not qualify if…

• Participants with best-corrected visual acuity (BCVA) worse than 20 early treatment diabetic retinopathy study (ETDRS) letters in at least one eye.
• Participants with confirmed or suspected uveitis of infectious etiology or uveitis of traumatic etiology.
• Participants with primary diagnosis of anterior uveitis.
• Prior treatment with anti-interleukin-6 (IL-6) or interleukin-6 receptor complex (IL-6R) antagonist therapies, including tocilizumab and sarilumab.
• The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 840008 — Worcester, Massachusetts, United States
• Investigational Site Number 840009 — Omaha, Nebraska, United States
• Investigational Site Number 840005 — Slingerlands, New York, United States
• Investigational Site Number 840007 — Cleveland, Ohio, United States
• Investigational Site Number 840006 — Arlington, Texas, United States
• Investigational Site Number 203001 — Brno, Czechia
• Investigational Site Number 203002 — Prague, Czechia
• Investigational Site Number 250001 — Paris, France
• Investigational Site Number 250002 — Paris, France
• Investigational Site Number 380001 — Milan, Italy
• Investigational Site Number 380003 — Padova, Italy
• Investigational Site Number 380004 — Reggio Emilia, Italy
• Investigational Site Number 724003 — Barcelona, Spain
• Investigational Site Number 724001 — Barcelona, Spain
• Investigational Site Number 792001 — Ankara, Turkey (Türkiye)
• Investigational Site Number 792005 — Ankara, Turkey (Türkiye)
• Investigational Site Number 792002 — Istanbul, Turkey (Türkiye)
• Investigational Site Number 792003 — Istanbul, Turkey (Türkiye)
• Investigational Site Number 792004 — Izmir, Turkey (Türkiye)
• Investigational Site Number 792006 — Izmir, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.